|
KMID : 1039120220110010096
|
|
Clinical and Experimental Vaccine Research
2022 Volume.11 No. 1 p.96 ~ p.103
|
|
|
Large inter-individual variability of cellular and humoral immunological responses to mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in health care workers
|
|
Kruttgen Alexander
Haase Gerhard
Haefner Helga
Imohl Matthias
Kleines Michael
|
|
|
Abstract
|
|
|
Purpose: Studies on the immune responses to severe acute respiratory syndrome coronavirus 2 vaccines are necessary to evaluate the ongoing vaccination programs by correlating serological response data and clinical effectiveness data. We performed a longitudinal immunological profiling of health care workers vaccinated with mRNA-1273 (Moderna, Cambridge, MA, USA). Half of these vaccinees had experienced a mild coronavirus disease 2019 (COVID-19) infection in the spring of 2020 (“COVID-recovered” cohort), whereas the other half of the vaccinees had no previous COVID-19 infection (“COVID-naive” cohort).
Materials and Methods: Serum was drawn at multiple time points and subjected to assays measuring anti-Spike immunoglobulin G (IgG), avidity of anti-Spike IgG, avidity of anti-receptor binding domain (RBD) IgG, virus neutralizing activity, and interferon-γ release from stimulated lymphocytes.
Results: Between both cohorts and within each cohort, we found remarkable inter-individual differences regarding cellular and humoral immune responses to the Moderna mRNA-1273 vaccine.
Conclusion: First, our study indicates that the success of mRNA-1273 vaccinations should be verified by serological assays in order to identify “low-responders” to vaccination. Second, the kinetics of anti-S IgG and neutralizing activity correlate well with clinical effectiveness data, thus explaining incipient protection against infection 2 weeks after the first dose of mRNA-1273 in COVID-naive vaccinees. Third, our IgG-avidity data indicate that this incipient protection is mediated by low-avidity anti-RBD IgG and low-avidity anti-S IgG.
|
|
|
KEYWORD
|
|
|
COVID-19, Non-responders, Vaccination, Avidity, SARS-CoV-2
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|